未遵循头颈部鳞癌治疗指南的机构财务毒性
该研究基于退伍军人健康管理局(VHA)机构队列(n=338)和标准化队列(n=100),评估未达到头颈鳞癌治疗时间指标所导致的机构财务毒性。研究计算了诊断至治疗启动时间、手术至术后放疗时间及总治疗包时间的财务毒性,结果显示未达标会产生显著但可避免的机构财务毒性。
要点
- 未达标治疗时间指标产生显著但可避免的机构财务毒性
- 财务毒性在单支付方整合系统(如VHA)中尤为 relevant
- 免疫治疗时代需关注治疗延迟带来的额外成本
核心结论
- 未达到既定头颈鳞癌治疗时间指标会产生显著但可避免的机构财务毒性。
研究设计与样本
- 基于VHA机构队列(n=338)和标准化队列(n=100)的财务毒性计算研究。
- 识别三项治疗指标:诊断至治疗启动时间(TTI)、手术至术后放疗时间(surg→PORT)、总治疗包时间(TPT)。
- 财务毒性使用风险比、帕博利珠单抗成本及给药数据计算。
主要发现
- VHA队列中TTI、surg→PORT、TPT的估计财务毒性分别为$2 047 407、$316 545、$1 114 101。
- 标准化队列中TTI、surg→PORT、TPT的估计财务毒性分别为$454 028、$544 576、$1 879 628。
临床怎么用
- 临床应严格遵循头颈鳞癌治疗时间指标以减少可避免的机构财务毒性。
- 在免疫治疗时代,尤其单支付方系统中,治疗延迟的财务后果需纳入质量改进考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delays in treatment of head and neck squamous cell carcinoma (HNSCC) are known to increase disease recurrence, generating the need for additional salvage treatment, often with immunotherapy. METHODS: Three treatment metrics were identified: time from diagnosis to treatment initiation (TTI), time from surgery to postoperative radiotherapy (surg → PORT), and total treatment package time (TPT). Financial toxicity was calculated using hazard ratios, pembrolizumab cost, and dosing data for a Veterans Health Administration (VHA) institutional cohort (n = 338) and a standardized cohort (n = 100). RESULTS: Estimated financial toxicity for the VHA cohort was $2 047 407, $316 545, and $1 114 101 for TTI, surg → PORT, and TPT, respectively. Estimated financial toxicity for the standardized patient cohort was $454 028, $544 576, and $1 879 628 for TTI, surg → PORT, and TPT, respectively. CONCLUSIONS: Failure to meet established HNSCC treatment metrics generates significant, yet avoidable, institutional financial toxicity which is particularly relevant to integrated single-payer systems such as the VHA in the modern immunotherapy era.
引用
- Jurica JM, Rubio F, Hernandez DJ, et al. Institutional financial toxicity of failure to adhere to treatment guidelines for head and neck squamous cell carcinoma. Head Neck. 2020. PMID: 33166016. doi:10.1002/hed.26539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。